Collaborative Engagement on Access to Medicine and SDG3

62 members

The 2024 Access to Medicine Index analyses 20 of the largest research-based pharmaceutical companies on their efforts to improve access to essential medicines for 81 high-burden diseases across 113 low- and middle-income countries (LMICs).

The Index is endorsed by over 145 investors, collectively managing assets worth over USD 22 trillion.

Type
Engagement or initiative
Status
Seeking support
Deadline
31 December 2025
Contact
Avanti Gupta
Collaboration details

The Access to Medicine Index measures a range of value drivers within the pharmaceutical business model, including governance, R&D, pricing and compliance. The collaborative engagement covers the 19 listed companies in the 2024 Access to Medicine Index. 

Expanding access to medicine will help pharma companies enhance shareholder value in several ways:

  • Unlock growth potential in emerging markets by reaching new populations.
  • Mitigate the risk of unethical conduct.
  • Enhance corporate reputations.
  • Contribute to the creation of healthy societies.

You can read more here.

Companies covered in the collaborative engagement: AbbVie Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Co., Daiichi-Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly & Co., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Merck & Co., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Roche Holding AG, Sanofi, Takeda Pharmaceutical Co. Ltd.

Engagement focus

Created on
ESG theme
  • Social
ESG sub-theme
  • Human rights
  • Public health
Sector
  • Health Care
Sustainable Development Goal
  • 3 - Good health & well-being
Geography
  • Global
Asset class
All